NEW YORK, June 19 - Genomica said Tuesday it had appointed Michael Savage, formerly CEO of Molecular Simulations, to its board of directors.

Savage will replace Arnold Levine, who is joining Genomica's scientific advisory board.

Savage was CEO of Molecular Simulations for eight years before the company was acquired by Pharmacopeia in 1998.

Genomica of Boulder, Colo., develops and markets software products and services, designed to enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.